Sci Signal:p53受癌细胞中的有氧糖酵解作用的调控

2020-06-03 MedSci原创 MedSci原创

利用人乳腺癌细胞模型,研究人员确定了一种途径,其中线粒体外NADH:NAD+比值的变化通过CtBP家族的NADH敏感转录调控剂控制p53的丰度和活性。

癌细胞中的高糖酵解率是许多人类肿瘤的一个既定特征,它为迅速增殖的癌细胞提供了可用作合成代谢途径的前体的代谢产物。高糖化率的维持依赖于乳酸脱氢酶催化的NAD+的再生,因为NADH:NAD+比例的增加会抑制GAPDH。

最近,利用人乳腺癌细胞模型,研究人员确定了一种途径,其中线粒体外NADH:NAD+比值的变化通过CtBP家族的NADH敏感转录调控剂控制p53的丰度和活性。NADH-free形式的CtBPs与p53结合伙伴HDM2合作,抑制p53功能,而NADH-free形式的CtBPs在高度糖酵解细胞中的缺失导致p53的蓄积。

研究人员表明,这一途径代表了一种 "糖酵解应激反应",通过增加NADH:NAD+比例启动保护性的p53反应,使细胞避免了代谢供需不匹配造成的细胞损伤。

 

原始出处:

Charles N. Birts et al. p53 is regulated by aerobic glycolysis in cancer cells by the CtBP family of NADH-dependent transcriptional regulators, Science Signaling (2020). DOI: 10.1126/scisignal.aau9529

 

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=971961, encodeId=1fff9e196184, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ebc5153056, createdName=1469e2dem16(暂无昵称), createdTime=Tue Jun 08 20:53:17 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794020, encodeId=4d3f1e940200c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sat Jan 02 01:07:51 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036205, encodeId=99d5203620516, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Jul 16 20:07:51 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252702, encodeId=735c1252e02f8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275777, encodeId=55e812e5777c6, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372426, encodeId=70c113e24264c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=)]
    2021-06-08 1469e2dem16(暂无昵称)

    不错

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=971961, encodeId=1fff9e196184, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ebc5153056, createdName=1469e2dem16(暂无昵称), createdTime=Tue Jun 08 20:53:17 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794020, encodeId=4d3f1e940200c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sat Jan 02 01:07:51 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036205, encodeId=99d5203620516, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Jul 16 20:07:51 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252702, encodeId=735c1252e02f8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275777, encodeId=55e812e5777c6, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372426, encodeId=70c113e24264c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=)]
    2021-01-02 yaanren
  3. [GetPortalCommentsPageByObjectIdResponse(id=971961, encodeId=1fff9e196184, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ebc5153056, createdName=1469e2dem16(暂无昵称), createdTime=Tue Jun 08 20:53:17 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794020, encodeId=4d3f1e940200c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sat Jan 02 01:07:51 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036205, encodeId=99d5203620516, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Jul 16 20:07:51 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252702, encodeId=735c1252e02f8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275777, encodeId=55e812e5777c6, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372426, encodeId=70c113e24264c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=)]
    2020-07-16 楚秀娟
  4. [GetPortalCommentsPageByObjectIdResponse(id=971961, encodeId=1fff9e196184, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ebc5153056, createdName=1469e2dem16(暂无昵称), createdTime=Tue Jun 08 20:53:17 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794020, encodeId=4d3f1e940200c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sat Jan 02 01:07:51 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036205, encodeId=99d5203620516, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Jul 16 20:07:51 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252702, encodeId=735c1252e02f8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275777, encodeId=55e812e5777c6, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372426, encodeId=70c113e24264c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=)]
    2020-06-05 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=971961, encodeId=1fff9e196184, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ebc5153056, createdName=1469e2dem16(暂无昵称), createdTime=Tue Jun 08 20:53:17 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794020, encodeId=4d3f1e940200c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sat Jan 02 01:07:51 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036205, encodeId=99d5203620516, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Jul 16 20:07:51 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252702, encodeId=735c1252e02f8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275777, encodeId=55e812e5777c6, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372426, encodeId=70c113e24264c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=971961, encodeId=1fff9e196184, content=不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3ebc5153056, createdName=1469e2dem16(暂无昵称), createdTime=Tue Jun 08 20:53:17 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794020, encodeId=4d3f1e940200c, content=<a href='/topic/show?id=7b3d1630617' target=_blank style='color:#2F92EE;'>#Signal#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16306, encryptionId=7b3d1630617, topicName=Signal)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=102a153, createdName=yaanren, createdTime=Sat Jan 02 01:07:51 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2036205, encodeId=99d5203620516, content=<a href='/topic/show?id=ae7816304dc' target=_blank style='color:#2F92EE;'>#Sign#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16304, encryptionId=ae7816304dc, topicName=Sign)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9ed371, createdName=楚秀娟, createdTime=Thu Jul 16 20:07:51 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252702, encodeId=735c1252e02f8, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1275777, encodeId=55e812e5777c6, content=<a href='/topic/show?id=22a8e68696b' target=_blank style='color:#2F92EE;'>#糖酵解#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76869, encryptionId=22a8e68696b, topicName=糖酵解)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2978132, createdName=minzju5052, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1372426, encodeId=70c113e24264c, content=<a href='/topic/show?id=9d861362e53' target=_blank style='color:#2F92EE;'>#p53#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13627, encryptionId=9d861362e53, topicName=p53)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5d70341, createdName=zhishijing, createdTime=Fri Jun 05 01:07:51 CST 2020, time=2020-06-05, status=1, ipAttribution=)]
    2020-06-05 zhishijing

相关威廉亚洲官网

Cancer Immunol Immunother:肿瘤免疫微环境对白细胞增多症患者的影响

肿瘤相关白细胞增多症(TRL)与各种类型的癌症的生存能力差相关,但TRL相关的人类肿瘤的微环境尚未完全阐明。在此,williamhill asia 旨在描述TRL相关癌症患者的免疫微环境。

Lancet:肿瘤患者新冠肺炎死亡率较高

肿瘤患者的新冠肺炎30天死亡率较高,一般风险因素以及肿瘤患者特定风险因素均发挥了较大作用

NATURE:相位和形成背景共同塑造了复合型致癌突变的功能

癌症的发展是由于驱动力突变,导致了克隆性增殖和疾病的演变。个别驱动突变的发现和功能表征是癌症研究的核心目标,并阐明了无数的表型和治疗漏洞。

SCIENCE:人类肿瘤细胞内的细菌竟有细胞特异性!

研究人员对肿瘤微生物组进行了全面的分析,研究了1526个肿瘤及其邻近的正常组织,涉及乳腺癌、肺癌、卵巢癌、胰腺癌、黑色素瘤、骨肿瘤和脑肿瘤等7种肿瘤类型。

Genes Dev:研究揭示YAP/TAZ诱导AP-1有助于细胞增殖和器官生长

Yes相关蛋白 (YAP)及其同源的转录共激活因子PDZ-binding motif (TAZ)是控制细胞生长和器官大小的Hippo通路的关键效应因子,其失调会导致肿瘤发生或肥大。激活后,YAP/TA

2020年华大基因肿瘤医学成果展示:3款全新肿瘤检测技术,助力癌症防控

2020华大基因肿瘤技术成果研讨与发布会”上,华大基因在线发布了三款肿瘤检测技术:基于甲基化快速靶向测序EpiPlexTM的肝癌早检技术 、同源重组缺陷(HRD)检测技术(GSA)、实体瘤患者定制化监